Acorda Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Net revenues
Net Product Revenues
Milestone Revenues
Royalty Revenues
License Revenue
Total net revenues

Costs and expenses:
Cost of sales
Research and development
Selling, general and administrative
Intangible asset impairments
Loss on assets held for sale
Intangible asset impairment
Amortization of intangible assets
Changes in fair value of derivative liability
Changes in fair value of acquired contingent consideration
Other operating income
Total operating expenses

Operating loss
Other income (expense), net:
Interest and amortization of debt discount expense
Interest income
Realized Gain (Loss) on FX Currency
Gain on extinguishment of debt
Gain on disposal of property and equipment
Other income (expense)
Total other income (expense), net
Loss before taxes
Benefit from (Provision for) income taxes
Net loss
Net loss per share—basic
Net loss per share—diluted
Weighted average common shares outstanding used in computing net loss per share—basic
Weighted average common shares outstanding used in computing net loss per share—diluted

Comments